11 patents currently held
7 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jan 2028. from the record
Of the 7 now held by other companies, 6 name Adamas Pharma LLC as their current owner, and 1 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
3
Ending by 2030
Jan 2028
Next term end
5
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jan 2028 · High confidence
Also notable
Ends Dec 2029 · High confidence
Also notable
Ends no later than Apr 2028 · Medium confidence
Composition and Method for Treating Neurological Disease
US 8,389,578
The most cited patent in this portfolio, cited by 137 later US patents, top 5% of utility patents granted in 2013 in our data. Protection runs to 2028.
Methods and Compositions for the Treatment of Cns-Related Conditions
US 8,058,291
Cited by 84 later US patents, top 10% of utility patents granted in 2011 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029.
Compositions and Kits for Treating Influenza
US 7,858,660
Cited by 32 later US patents, top 25% of utility patents granted in 2010 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2028. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Formerly held, still cited
Notable
Ends Dec 2030 · High confidence
Cited by 29 later US patents, top 10% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2030. A terminal disclaimer caps this term to an earlier patent's.
now held by Adamas Pharma, LLC
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 5 fees due Jun 5 to 24, 2027 · next Jun 5
- 1 fee due Aug 6, 2027The maintenance fee for Composition and Method for Treating Neurological Disease (US 11,890,261) comes due Aug 6, 2027. Unpaid by Feb 7, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Composition and Method for Treating Neurological Disease (2018) | 4 in force | to Feb 2038 |
| Composition and Method for Treating Neurological Disease (2018) | 4 in force | to Feb 2038 |
| Methods and Compositions for the Treatment of Cns-Related Conditions | 1 in force | to Dec 2029 |
| Compositions and Kits for Treating Influenza | 1 in force | to Apr 2028 |
| Composition and Method for Treating Neurological Disease (2005) | 1 in force | to Jan 2028 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,389,578 | Composition and Method for Treating Neurological Disease In force · High confidence | In force | High confidence | |
| US 7,858,660 | Compositions and Kits for Treating Influenza In force · Medium confidence | In force | Medium confidence | |
| US 8,058,291 | Methods and Compositions for the Treatment of Cns-Related Conditions In force · High confidence | In force | High confidence | |
| US 10,213,393 | Composition and Method for Treating Neurological Disease In force · High confidence | In force | High confidence | |
| US 10,213,394 | Composition and Method for Treating Neurological Disease In force · High confidence | In force | High confidence | |
| US 10,500,170 | Composition and Method for Treating Neurological Disease In force · High confidence | In force | High confidence | |
| US 10,500,171 | Composition and Method for Treating Neurological Disease In force · High confidence | In force | High confidence | |
| US 10,500,172 | Composition and Method for Treating Neurological Disease In force · High confidence | In force | High confidence | |
| US 10,512,617 | Composition and Method for Treating Neurological Disease In force · High confidence | In force | High confidence | |
| US 11,833,121 | Composition and Method for Treating Neurological Disease In force · High confidence | In force | High confidence |
Also on record, not counted in the 11: 7 patents in force now held by others · 26 patents ended · 59 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.